Pharmacokinetic Principles and Clinical Applications

The elimination half-life (t½) is the time required for the plasma concentration of a drug to fall by 50 percent. For drugs that follow first-order kinetics — where the rate of elimination is proportional to the drug concentration — the half-life is constant regardless of the starting concentration. The mathematical relationship governing half-life is: t½ = (0.693 × Vd) / CL, where Vd is the volume of distribution and CL is the total body clearance.

This equation has several important clinical interpretations. Half-life is not simply a measure of how fast a drug is eliminated — it is a composite parameter that reflects both how large the distribution space is (Vd) and how efficiently the eliminating organs remove drug from plasma (CL). A drug with a large Vd will have a long half-life even if its clearance is normal, because the large tissue reservoir slowly releases drug back into plasma. Conversely, a drug with a small Vd may have a short half-life even with modest clearance. When a patient's renal function declines, CL falls and t½ prolongs proportionally, but Vd may be unchanged or may itself change depending on the patient's fluid status and protein binding.

After each half-life, 50 percent of the remaining drug is eliminated. The cumulative elimination at successive half-lives is 50 percent, 75 percent, 87.5 percent, 93.75 percent, and 96.875 percent. By five half-lives, approximately 97 percent of a single dose has been eliminated, which is considered effectively complete for practical purposes. This 5 half-lives rule applies symmetrically: just as it takes 5 half-lives to eliminate a drug, it also takes 5 half-lives to reach steady state during repeated dosing.

The clinical implications are direct. A drug with a half-life of 6 hours reaches steady state in approximately 30 hours (5 × 6 hours). A drug with a half-life of 4 days (digoxin, half-life approximately 36 to 48 hours) takes approximately 7 to 10 days of maintenance dosing to reach steady state. A drug with a half-life of weeks (amiodarone) may take months of continuous dosing to reach steady state. This prediction of time-to-steady-state is entirely determined by the half-life — the dose size and dosing frequency affect the steady-state concentration level but not the time to reach it.

At steady state, the rate of drug input equals the rate of drug elimination. This means that the average steady-state plasma concentration is determined entirely by the dose rate (dose divided by dosing interval) and the clearance: average steady-state concentration equals dose rate divided by clearance. Clearance is therefore the pharmacokinetic parameter that determines how much drug accumulates in the body at a given dose rate. Volume of distribution affects the half-life and the time to reach steady state, but has no effect on the steady-state concentration itself. This distinction is clinically important: if a patient has a low clearance (renal or hepatic impairment), the steady-state concentration will be higher for the same dose rate — and the dose must be reduced to prevent toxicity. If a patient has an increased volume of distribution (edema, obesity), the time to reach steady state will be longer, but the same maintenance dose will ultimately produce the same average concentration once steady state is achieved.

Nonlinear pharmacokinetics arise when the enzymatic or transport system responsible for a drug's elimination becomes saturated. At low drug concentrations, the elimination system has spare capacity and behaves as if it were first-order: a constant fraction of drug is cleared per unit time, the half-life is constant, and concentration falls exponentially. As concentration rises toward the maximum rate at which the elimination system can operate (designated Vmax in the Michaelis-Menten model), the fractional clearance decreases — a smaller and smaller fraction of the drug present is eliminated per unit time. At concentrations far exceeding the elimination system's capacity, the system operates at its maximum rate regardless of concentration: a constant amount (not fraction) is eliminated per unit time, producing zero-order kinetics, where the half-life increases as concentration rises.

The consequence for clinical dosing is severe: in the Michaelis-Menten region, a small increase in dose produces a disproportionately large increase in steady-state plasma concentration. For a drug operating near saturation, an increase in daily dose of 10 percent may produce a 50 to 100 percent increase in steady-state concentration — a relationship that makes precise dose titration extremely difficult and toxicity easy to precipitate.

Phenytoin is the most clinically important example of Michaelis-Menten pharmacokinetics. It undergoes hepatic hydroxylation by cytochrome P450 2C9 and cytochrome P450 2C19, and the hydroxylation pathway becomes saturated near the lower end of the therapeutic range. For most patients, the Michaelis-Menten capacity (Km) for phenytoin hydroxylation is in the range of 5 to 10 micrograms per milliliter — squarely within the therapeutic range of 10 to 20 micrograms per milliliter. This means that patients being dose-titrated through the therapeutic range are operating in the nonlinear region where small dose changes produce large concentration changes.

The practical implication is that phenytoin doses should be titrated in small increments near the therapeutic range — typically increases of 25 to 50 milligrams per day — and that 4 to 6 weeks may be needed to achieve a new steady state because the effective half-life prolongs substantially as concentration rises. A patient whose phenytoin level is 15 micrograms per milliliter and who needs it at 18 micrograms per milliliter requires a very small dose increase; the same patient given the same incremental increase that would be appropriate for a linear drug could easily end up toxic at 35 micrograms per milliliter. Concurrent cytochrome P450 2C9 inhibitors (fluconazole, amiodarone) further displace phenytoin toward higher concentrations by reducing the already-limited elimination capacity.

Ethanol follows zero-order kinetics at typical drinking concentrations because alcohol dehydrogenase is saturated. The liver metabolizes approximately 7 to 10 grams of ethanol per hour in a typical adult regardless of blood alcohol concentration, which is why there is no way to accelerate sobriety — the elimination rate is fixed. Aspirin at anti-inflammatory doses (greater than approximately 1,000 milligrams per day) saturates sulfotransferase-mediated metabolism, shifting to zero-order kinetics and causing salicylate to accumulate disproportionately with dose increases — a pharmacokinetic fact that contributes to aspirin toxicity at high therapeutic doses. Fluorouracil and several other antineoplastic drugs also exhibit dose-dependent kinetics within therapeutic ranges used in oncology.

Neonates present the most extreme pharmacokinetic differences from adults. Cytochrome P450 enzyme expression is dramatically reduced at birth: cytochrome P450 3A4 is present at approximately 30 to 40 percent of adult activity in neonates, cytochrome P450 1A2 is nearly absent, and uridine diphosphate glucuronosyltransferase activity is approximately 25 percent of adult levels. These deficiencies explain the vulnerability to chloramphenicol (gray baby syndrome, as discussed in Module 3) and morphine toxicity. Glomerular filtration rate in neonates is approximately 2 to 4 milliliters per minute per kilogram, reaching adult values (approximately 1.5 milliliters per minute per kilogram, equivalent to the adult 100 to 125 milliliters per minute in a 70-kilogram adult) only by 6 to 12 months of age. Total body water as a fraction of body weight is higher in neonates (approximately 75 to 80 percent) than adults (approximately 60 percent), increasing the volume of distribution for hydrophilic drugs.

Plasma albumin and alpha-1-acid glycoprotein concentrations are lower in neonates, reducing protein binding of both acidic and basic drugs and increasing free fractions. Gastric acid secretion is reduced at birth, raising gastric pH and altering the dissolution and absorption of pH-dependent drugs. The net result is that virtually every pharmacokinetic parameter differs substantially from adults in neonates, and weight-based adult dosing converted to milligrams per kilogram is generally insufficient — neonatal dosing must account for these specific immaturities.

Aging produces progressive and predictable changes in pharmacokinetics that make elderly patients significantly more sensitive to many drugs. Renal function declines with age even without overt kidney disease: the average glomerular filtration rate falls by approximately 1 milliliter per minute per year after age 40. Because serum creatinine also falls with age due to decreased muscle mass, the creatinine-based estimation of glomerular filtration rate can be deceptively normal while true filtration capacity is substantially reduced. Renally cleared drugs therefore require dose reduction in elderly patients even when the serum creatinine is apparently normal.

Hepatic blood flow decreases with age, reducing the first-pass metabolism and increasing the oral bioavailability of high-extraction drugs (lidocaine, propranolol, morphine). Phase one cytochrome P450 activity declines modestly with age; phase two glucuronidation is relatively preserved. Body composition changes: lean muscle mass decreases and adipose tissue increases, enlarging the volume of distribution of lipophilic drugs and prolonging their half-lives while reducing the volume of distribution of hydrophilic drugs. Plasma albumin falls modestly, increasing free fractions of albumin-bound drugs. These changes combine to make elderly patients more susceptible to drug accumulation, adverse effects, and drug-drug interactions at doses appropriate for younger adults.

Pregnancy alters virtually every pharmacokinetic parameter to varying degrees over the three trimesters. Renal blood flow and glomerular filtration rate increase by 40 to 50 percent during pregnancy, substantially increasing the renal clearance of drugs eliminated by filtration. This increase in clearance for renally cleared drugs (including certain antibiotics, lithium, and some antiepileptics) means that pregnancy may require dose increases to maintain therapeutic concentrations. Plasma volume expands by approximately 45 percent, increasing the volume of distribution of hydrophilic drugs and diluting plasma drug concentrations. Plasma albumin falls by approximately 10 to 15 percent, increasing free fractions of albumin-bound drugs. Gastric emptying slows (particularly in the first trimester, associated with nausea), delaying absorption and lowering peak concentrations of orally administered drugs. Cytochrome P450 3A4 and cytochrome P450 2D6 activities increase during pregnancy (due to progesterone-mediated induction), accelerating the clearance of their substrates and potentially requiring dose increases for antiretrovirals, antiepileptics, and other cytochrome P450 3A4 or 2D6 substrates.

The pharmacokinetic consequences of obesity are primarily driven by the altered body composition (increased adipose tissue, increased lean body mass relative to a normal-weight person of the same height, expanded blood volume and cardiac output) and by the fact that adipose tissue distributes lipophilic drugs extensively but not hydrophilic drugs. For dosing purposes, the key practical rule — already introduced in Module 2 — is that lipophilic drugs should generally be dosed based on total body weight in obese patients, because adipose tissue contributes to their distribution volume, while hydrophilic drugs should be dosed based on lean or ideal body weight. Specific adjustment factors exist for individual drugs, and drug-specific literature should be consulted for critical medications in severely obese patients.

Clearance (CL) is the volume of plasma completely cleared of drug per unit time. It is expressed in units of volume per time (milliliters per minute or liters per hour) and represents the efficiency with which the body removes drug. Clearance is the pharmacokinetic parameter that most directly determines the steady-state plasma concentration for a given maintenance dose: at steady state, the rate of drug input equals the rate of drug removal, so steady-state concentration equals the dose rate divided by clearance. This means that if clearance is halved by renal impairment or enzyme inhibition, the steady-state concentration doubles at the same dose — a proportional relationship that is the pharmacokinetic rationale for dose adjustment when clearance changes.

Total body clearance is the sum of all elimination pathways: hepatic clearance (from metabolism and biliary excretion), renal clearance (filtration plus secretion minus reabsorption), and all minor pathways. For a drug cleared 70 percent by the kidneys and 30 percent by the liver, a 50 percent reduction in renal function reduces total clearance by approximately 35 percent — not 50 percent — because hepatic clearance is unaffected. This proportional thinking is essential for dose adjustment in organ impairment.

The elimination half-life (t½) is the time required for the plasma drug concentration to fall by 50 percent during the elimination phase. It is not an independent parameter but a derived one: t½ = (0.693 × Vd) / CL. This equation reveals two clinically important facts. First, half-life increases when the volume of distribution increases — a drug that accumulates extensively in tissue has a large reservoir that slowly releases drug back into plasma, prolonging the time to full elimination even if clearance is normal. This is why amiodarone has a half-life measured in weeks despite reasonable hepatic clearance. Second, half-life decreases when clearance increases — a highly efficient eliminating organ reduces the time for each 50 percent decrement in concentration.

The practical rule derived from half-life mathematics is that 97 percent of a drug is eliminated after five half-lives, and 97 percent of the theoretical steady-state concentration is reached after five half-lives of repeated dosing. These five-half-life rules govern washout periods in clinical trials, medication transition timing, and the time clinicians must wait before drug levels become interpretable after initiating or changing therapy.

A common misconception is that increasing the volume of distribution raises or lowers the steady-state concentration. It does not. At true steady state, the average plasma concentration depends only on the dose rate and clearance: average steady-state concentration equals dose rate divided by clearance. Volume of distribution affects how long it takes to reach steady state (through its effect on half-life) and how much the concentration fluctuates within each dosing interval, but not the average steady-state level. This distinction matters clinically: two drugs with very different volumes of distribution but identical clearances will reach the same average steady-state concentration at the same dose rate — they just take different amounts of time to get there.

Enzymes have a maximum rate at which they can process substrate — the maximum velocity (Vmax). At low substrate concentrations, the enzyme is far from saturated and the rate of metabolism is proportional to drug concentration (first-order kinetics: doubling the concentration doubles the rate of elimination). As drug concentration increases toward the enzyme's capacity, the rate of elimination approaches Vmax asymptotically. At very high concentrations, the enzyme is fully saturated and eliminates drug at a constant rate regardless of concentration — zero-order kinetics (a fixed amount of drug eliminated per unit time rather than a fixed fraction).

The clinically important consequence of nonlinear kinetics is that there is no longer a proportional relationship between dose and steady-state concentration. As the dose is increased toward the metabolic capacity ceiling, each additional increment of dose produces a disproportionately larger rise in steady-state concentration. This dose-concentration relationship becomes increasingly steep as saturation is approached, making dosing unpredictable and dangerous.

Phenytoin is the most clinically important drug exhibiting nonlinear pharmacokinetics because it is metabolized by cytochrome P450 2C9 (and to a lesser extent cytochrome P450 2C19), and these enzymes become substantially saturated at phenytoin concentrations within the therapeutic range (10 to 20 micrograms per milliliter). This means that phenytoin operates in a pharmacokinetic danger zone where small dose changes can produce large concentration changes.

A patient whose phenytoin concentration is 12 micrograms per milliliter on a dose of 300 milligrams per day may reach a toxic concentration of 25 micrograms per milliliter when the dose is increased to 350 milligrams per day — a modest-appearing 17 percent dose increase that produces a clinically dangerous concentration because the enzymes are already near saturation. The practical implication is that phenytoin dose adjustments should be made in small increments (25 to 50 milligrams per day rather than large jumps), and adequate time to reach the new steady state must be allowed before the next adjustment. Because phenytoin also has a long half-life (approximately 20 to 60 hours depending on the dose and concentration) and the half-life itself increases as concentration rises due to saturation, reaching steady state can take weeks at higher doses.

Ethanol and aspirin at high doses are two additional drugs that exhibit saturable elimination at clinically relevant concentrations. Ethanol is metabolized at a constant rate by alcohol dehydrogenase (approximately 7 to 10 grams per hour in adults) regardless of blood alcohol concentration — the classic zero-order kinetics — which is why blood alcohol concentration falls linearly rather than exponentially over time after drinking stops. Aspirin at anti-inflammatory doses (greater than 2 to 3 grams per day) saturates the hepatic sulfotransferase pathway and shifts to longer and variable half-lives.

Neonates differ from adults across every pharmacokinetic domain. Their total body water as a proportion of body weight is substantially greater (approximately 75 to 80 percent versus 60 percent in adults), giving hydrophilic drugs a larger volume of distribution per kilogram. Plasma albumin concentrations are lower at birth, increasing the free fraction of highly albumin-bound drugs. Hepatic cytochrome P450 enzyme expression is markedly reduced at birth: cytochrome P450 3A4, cytochrome P450 2C9, and cytochrome P450 2D6 activities are 5 to 30 percent of adult levels at term and mature over the first weeks to months of life. Phase two conjugation pathways are similarly immature: glucuronidation (as demonstrated by chloramphenicol gray baby syndrome) and sulfation capacity are substantially below adult levels at birth. Renal glomerular filtration rate in a term neonate is approximately 20 to 30 percent of the adult rate per unit body surface area, rising to adult values by 6 to 12 months. Together, these factors mean that neonates clear most drugs much more slowly than adults, and that doses must be carefully scaled not only for body weight but for developmental stage.

Age-related physiological changes alter pharmacokinetics in predictable directions. Renal function declines with age even in the absence of recognized kidney disease: glomerular filtration rate falls approximately 0.75 to 1 milliliter per minute per year after age 40, so a 75-year-old patient may have a glomerular filtration rate of 50 percent of the young-adult baseline. Because serum creatinine is a product of muscle mass, and elderly patients have reduced muscle mass, the serum creatinine may appear normal despite significantly reduced renal function. Creatinine-based estimates of glomerular filtration rate must account for age and weight to avoid interpreting a falsely normal creatinine as normal renal clearance.

Hepatic blood flow decreases approximately 30 to 40 percent with age, reducing the clearance of high-extraction drugs (morphine, propranolol, lidocaine) that depend on flow-limited delivery to the liver. Body composition changes: fat mass increases as lean mass decreases, increasing the volume of distribution for lipophilic drugs (benzodiazepines accumulate more extensively, producing prolonged sedation). Plasma albumin tends to fall modestly in elderly patients who are ill or malnourished, increasing the free fraction of acidic drugs. The net pharmacokinetic effect in elderly patients is typically reduced clearance and prolonged half-lives, requiring lower maintenance doses and greater attention to accumulation risk.

Pregnancy produces substantial changes in maternal pharmacokinetics across all four domains of absorption, distribution, metabolism, and elimination. Blood volume increases 40 to 50 percent and total body water increases substantially, enlarging the volume of distribution for most drugs. Renal blood flow and glomerular filtration rate increase 50 to 60 percent above baseline by the third trimester, increasing the renal clearance of drugs eliminated by filtration. Hepatic cytochrome P450 3A4 and cytochrome P450 2D6 activity increases during pregnancy (estrogen and progesterone upregulate expression), while cytochrome P450 1A2 and cytochrome P450 2C19 are modestly inhibited. Gastric emptying slows in the first trimester (increasing the time to peak concentration for oral drugs) and the large uterus elevates abdominal pressure in the third trimester, reducing gastrointestinal absorption reliability.

The practical consequence for drugs requiring therapeutic monitoring in pregnant patients — antiepileptics, antiretrovirals, antibiotics for systemic infections — is that concentrations may fall substantially during pregnancy despite unchanged doses, potentially leading to treatment failure. Monitoring drug levels more frequently and adjusting doses upward during pregnancy is appropriate for these drugs, with post-partum reduction back to pre-pregnancy doses as clearance returns to baseline within weeks of delivery.

Obesity creates pharmacokinetic heterogeneity that depends primarily on whether the drug distributes into adipose tissue. As discussed in Module 2, lipophilic drugs have increased volume of distribution in obese patients (more adipose reservoir), while hydrophilic drugs distribute primarily into lean body mass and extracellular fluid, which increases less proportionally with total body weight. The practical dosing rule is to use total body weight for loading doses of lipophilic drugs and lean body weight (or adjusted body weight) for loading doses of hydrophilic drugs.

Renal clearance often increases in obesity due to elevated glomerular filtration rate from hyperfiltration of the enlarged nephron mass, which can increase the elimination of renally cleared drugs and require higher doses than standard weight-based calculations predict. Hepatic clearance may also be modestly increased. The relevant pharmacokinetic issue in obesity is choosing the right weight scalar for the specific drug, rather than applying a single approach to all drug calculations.